<rdf:RDF xmlns:api="http://www.elsevier.com/xml/svapi/rdf/dtd/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874374884"><dc:identifier>https://api.elsevier.com/content/abstract/eid/2-s2.0-84874374884</dc:identifier><api:scopusId>84874374884</api:scopusId><api:eid>2-s2.0-84874374884</api:eid><api:pubmedId>23441766</api:pubmedId><api:pui>52271609</api:pui><prism:doi>10.1111/1756-185x.12002</prism:doi><dc:title>Belimumab: Targeted therapy for lupus</dc:title><prism:issn>17561841</prism:issn><prism:issn>1756185X</prism:issn><prism:contentType>Abstract</prism:contentType><prism:aggregationType>Journal</prism:aggregationType><api:srctype>j</api:srctype><api:subtype>re</api:subtype><api:subtypeDescription>Review</api:subtypeDescription><api:citedbyCount>5</api:citedbyCount><prism:publicationName>International Journal of Rheumatic Diseases</prism:publicationName><api:sourceId>12400154749</api:sourceId><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:startingPage>4</prism:startingPage><prism:endingPage>13</prism:endingPage><prism:pageRange>4-13</prism:pageRange><prism:coverDate>2013-02-01</prism:coverDate><prism:copyrightYear>2013</prism:copyrightYear><dc:creator><rdf:Seq><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/54402479900"><api:authid>54402479900</api:authid><api:surname>Chugh</api:surname><api:givenName>Preeta K.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60009217"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/23100643100"><api:authid>23100643100</api:authid><api:surname>Kalra</api:surname><api:givenName>Bhupinder S.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60009217"/></api:Author></rdf:li></rdf:Seq></dc:creator><dc:subject rdf:resource="http://data.elsevier.com/vocabulary/ASJC/2745"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84874382778"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/24344491492"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/70350180430"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/74849131972"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/75149150898"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/79952070370"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/82455198794"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84862002288"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84874355770"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84874354626"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/58549086734"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0033538468"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/67649853099"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0034972257"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/49449092839"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/79953170908"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/47249111687"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33646827589"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/54349100000"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/69749120918"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0032752441"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/79955039943"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/69749096135"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84874387012"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84874374885"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84874371527"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84874379435"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84874375835"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84874350064"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/84858751079"/><prism:keyword>Autoimmune disease</prism:keyword><prism:keyword>B lymphocyte stimulator</prism:keyword><prism:keyword>Belimumab</prism:keyword><prism:keyword>Benlysta</prism:keyword><prism:keyword>Lupus</prism:keyword><prism:keyword>Systemic lupus erythematosus</prism:keyword><api:scopusPage rdf:resource="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84874374884&amp;origin=inward"/></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60009217"><api:afid>60009217</api:afid><skos:prefLabel>Maulana Azad Medical College</skos:prefLabel></rdf:Description><rdf:Description rdf:about="http://data.elsevier.com/vocabulary/ASJC/2745"><api:code>2745</api:code><api:abbrev>MEDI</api:abbrev><skos:prefLabel>Rheumatology</skos:prefLabel><skos:altLabel>Medicine</skos:altLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874382778"><api:scopusId>84874382778</api:scopusId></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/24344491492"><api:scopusId>24344491492</api:scopusId><dc:title>Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices</dc:title><prism:publicationName>Best Pract Res Clin Rheumatol</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>19</prism:volume><prism:startingPage>685</prism:startingPage><prism:endingPage>708</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/70350180430"><api:scopusId>70350180430</api:scopusId><dc:title>Clinical trials for lupus - are we there yet?</dc:title><prism:publicationName>Bull NYU Hosp Jt Dis</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>67</prism:volume><prism:startingPage>267</prism:startingPage><prism:endingPage>270</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/74849131972"><api:scopusId>74849131972</api:scopusId><dc:title>Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>62</prism:volume><prism:startingPage>222</prism:startingPage><prism:endingPage>233</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/75149150898"><api:scopusId>75149150898</api:scopusId><dc:title>Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>60</prism:volume><prism:startingPage>429</prism:startingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/79952070370"><api:scopusId>79952070370</api:scopusId><dc:title>Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial</dc:title><prism:publicationName>Lancet</prism:publicationName><prism:publicationYear>2011</prism:publicationYear><prism:volume>377</prism:volume><prism:startingPage>721</prism:startingPage><prism:endingPage>731</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/82455198794"><api:scopusId>82455198794</api:scopusId><dc:title>A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2011</prism:publicationYear><prism:volume>63</prism:volume><prism:startingPage>3918</prism:startingPage><prism:endingPage>3930</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84862002288"><api:scopusId>84862002288</api:scopusId><dc:title>Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2012</prism:publicationYear><prism:startingPage>2328</prism:startingPage><prism:endingPage>2337</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874355770"><api:scopusId>84874355770</api:scopusId></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874354626"><api:scopusId>84874354626</api:scopusId><prism:publicationYear>2011</prism:publicationYear></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/58549086734"><api:scopusId>58549086734</api:scopusId><dc:title>The BLyS family: toward a molecular understanding of B cell homeostasis</dc:title><prism:publicationName>Cell Biochem Biophys</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>53</prism:volume><prism:startingPage>1</prism:startingPage><prism:endingPage>16</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0033538468"><api:scopusId>0033538468</api:scopusId><dc:title>BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator</dc:title><prism:publicationName>Science</prism:publicationName><prism:publicationYear>1999</prism:publicationYear><prism:volume>285</prism:volume><prism:startingPage>260</prism:startingPage><prism:endingPage>263</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/67649853099"><api:scopusId>67649853099</api:scopusId><dc:title>Cracking the BAFF code</dc:title><prism:publicationName>Nat Rev Immunol</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>9</prism:volume><prism:startingPage>491</prism:startingPage><prism:endingPage>502</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0034972257"><api:scopusId>0034972257</api:scopusId><dc:title>Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2001</prism:publicationYear><prism:volume>44</prism:volume><prism:startingPage>1313</prism:startingPage><prism:endingPage>1319</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/49449092839"><api:scopusId>49449092839</api:scopusId><dc:title>Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2008</prism:publicationYear><prism:volume>58</prism:volume><prism:startingPage>2453</prism:startingPage><prism:endingPage>2459</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/79953170908"><api:scopusId>79953170908</api:scopusId><prism:publicationName>Drugs R D</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>10</prism:volume><prism:startingPage>55</prism:startingPage><prism:endingPage>65</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/47249111687"><api:scopusId>47249111687</api:scopusId><dc:title>BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?</dc:title><prism:publicationName>Immunol Rev</prism:publicationName><prism:publicationYear>2008</prism:publicationYear><prism:volume>223</prism:volume><prism:startingPage>156</prism:startingPage><prism:endingPage>174</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33646827589"><api:scopusId>33646827589</api:scopusId><dc:title>Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects</dc:title><prism:publicationName>Toxicol Sci</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>1</prism:volume><prism:startingPage>586</prism:startingPage><prism:endingPage>599</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/54349100000"><api:scopusId>54349100000</api:scopusId><dc:title>Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus</dc:title><prism:publicationName>Arthritis Res Ther</prism:publicationName><prism:publicationYear>2008</prism:publicationYear><prism:volume>10</prism:volume></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/69749120918"><api:scopusId>69749120918</api:scopusId><dc:title>A phase II, randomized, double- blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>61</prism:volume><prism:startingPage>1168</prism:startingPage><prism:endingPage>1178</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0032752441"><api:scopusId>0032752441</api:scopusId><dc:title>Classification and definition of major flares in SLE clinical trials</dc:title><prism:publicationName>Lupus</prism:publicationName><prism:publicationYear>1999</prism:publicationYear><prism:volume>8</prism:volume><prism:startingPage>685</prism:startingPage><prism:endingPage>691</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/79955039943"><api:scopusId>79955039943</api:scopusId><dc:title>Five-year experience with belimumab, a BLyS-specific inhibitor, in patients with Systemic Lupus Erythematosus (SLE)</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2010</prism:publicationYear><prism:volume>62</prism:volume><prism:startingPage>1457</prism:startingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/69749096135"><api:scopusId>69749096135</api:scopusId><dc:title>Novel evidence-based systemic lupus erythematosus responder index</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2009</prism:publicationYear><prism:volume>61</prism:volume><prism:startingPage>1143</prism:startingPage><prism:endingPage>1151</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874387012"><api:scopusId>84874387012</api:scopusId></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874374885"><api:scopusId>84874374885</api:scopusId></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874371527"><api:scopusId>84874371527</api:scopusId></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874379435"><api:scopusId>84874379435</api:scopusId></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874375835"><api:scopusId>84874375835</api:scopusId></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84874350064"><api:scopusId>84874350064</api:scopusId></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/84858751079"><api:scopusId>84858751079</api:scopusId><dc:title>Lupus: novel therapies in clinical development</dc:title><prism:publicationName>Eur J Intern Med</prism:publicationName><prism:publicationYear>2012</prism:publicationYear><prism:volume>23</prism:volume><prism:startingPage>212</prism:startingPage><prism:endingPage>218</prism:endingPage></rdf:Description></rdf:RDF>